X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with AANJANEYA LIFECARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs DR. DATSONS LABS - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA DR. DATSONS LABS NATCO PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x 19.6 -10.9 - View Chart
P/BV x 18.7 0.2 11,543.0% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 NATCO PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
DR. DATSONS LABS
Mar-14
NATCO PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs877126 698.2%   
Low Rs42431 1,370.6%   
Sales per share (Unadj.) Rs223.4133.0 168.0%  
Earnings per share (Unadj.) Rs31.10.2 20,491.6%  
Cash flow per share (Unadj.) Rs40.36.6 609.5%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs219.5128.8 170.4%  
Shares outstanding (eoy) m33.0731.66 104.5%   
Bonus/Rights/Conversions PAFCCB-  
Price / Sales ratio x2.90.6 494.6%   
Avg P/E ratio x20.9516.1 4.1%  
P/CF ratio (eoy) x16.111.8 136.3%  
Price / Book Value ratio x3.00.6 487.6%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m21,5042,477 868.0%   
No. of employees `000NANA-   
Total wages/salary Rs m1,12856 2,013.8%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m7,3894,211 175.5%  
Other income Rs m16779 212.3%   
Total revenues Rs m7,5564,289 176.2%   
Gross profit Rs m1,793569 315.4%  
Depreciation Rs m304204 148.9%   
Interest Rs m366430 85.1%   
Profit before tax Rs m1,29013 10,155.9%   
Minority Interest Rs m460-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3096 5,060.7%   
Profit after tax Rs m1,0275 21,404.2%  
Gross profit margin %24.313.5 179.7%  
Effective tax rate %23.948.0 49.8%   
Net profit margin %13.90.1 12,197.0%  
BALANCE SHEET DATA
Current assets Rs m3,6816,852 53.7%   
Current liabilities Rs m3,1236,711 46.5%   
Net working cap to sales %7.63.3 225.7%  
Current ratio x1.21.0 115.5%  
Inventory Days Days89161 55.6%  
Debtors Days Days59318 18.4%  
Net fixed assets Rs m7,6853,673 209.2%   
Share capital Rs m331317 104.5%   
"Free" reserves Rs m6,6703,761 177.3%   
Net worth Rs m7,2594,078 178.0%   
Long term debt Rs m9551,671 57.2%   
Total assets Rs m11,95712,633 94.7%  
Interest coverage x4.51.0 439.2%   
Debt to equity ratio x0.10.4 32.1%  
Sales to assets ratio x0.60.3 185.4%   
Return on assets %11.73.4 338.5%  
Return on equity %14.20.1 12,023.4%  
Return on capital %20.77.7 270.1%  
Exports to sales %39.422.9 171.9%   
Imports to sales %5.714.3 39.9%   
Exports (fob) Rs m2,908964 301.6%   
Imports (cif) Rs m421602 70.0%   
Fx inflow Rs m3,445964 357.4%   
Fx outflow Rs m703607 115.8%   
Net fx Rs m2,743357 768.5%   
CASH FLOW
From Operations Rs m1,4401,345 107.1%  
From Investments Rs m-1,089-2,256 48.3%  
From Financial Activity Rs m-353-1,200 29.4%  
Net Cashflow Rs m-1-2,111 0.1%  

Share Holding

Indian Promoters % 52.0 4.5 1,148.8%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 0.0 -  
FIIs % 16.6 1.4 1,231.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 94.1 27.6%  
Shareholders   25,395 20,807 122.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   PANACEA BIOTECH  DISHMAN PHARMA  J.B.CHEMICALS  ASTRAZENECA PHARMA  DIVIS LABORATORIES  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6%

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jun 22, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - ALKEM LABORATORIES COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS